Journal
MULTIPLE SCLEROSIS AND RELATED DISORDERS
Volume 44, Issue -, Pages -Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.msard.2020.102315
Keywords
Ocrelizumab; Multiple Sclerosis; SARS-CoV-2; COVID-19; Immunuglobulins